Jared N. Schwartz, M.D., Ph.D., Joins Aperio as Chief Medical Officer
Press release from Aperio:
Global Digital Pathology Leader Strengthens Clinical Focus with Addition of Renowned Pathologist
Vista, CA – November 12, 2009 Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, has appointed Jared N. Schwartz, M.D., Ph.D, as its Chief Medical Officer (CMO).
Dr. Schwartz, former president of the Collegeof American Pathologists, is a leading advocate for improving patient care using technologies such as digital pathology. In his new role as Aperio’s CMO, Dr. Schwartz will continue to interact with the pathology community—including key opinion leaders, professional medical and advocacy societies, and medical directors of major clinical and regulatory organizations—about the benefits of digital pathology. In addition, he will develop and drive execution of Aperio’s clinical strategy in all medical and clinical efforts for scientific publications, product investigations and regulatory submissions. Dr. Schwartz will also provide medical input, perspective and vision to the executive management team and provide senior-level leadership for related functions.
“We are honored that a pathologist with Dr. Schwartz’s accomplishments is joining the market leader in digital pathology,” said Dirk G. Soenksen, CEO of Aperio. “We believe the clinical market is poised for rapid growth, and look forward to working together with Dr. Schwartz to develop and execute strategies for improving laboratory workflow and to identify opportunities for new image analysis tools. The medical leadership that Dr. Schwartz brings to Aperio will allow us to be more responsive to the needs of our growing installed base of clinical customers.”
Dr. Jared Schwartz commented, “The digital pathology market—fueled by demand for increased accuracy and efficiency of pathology services—is at a very exciting stage. The potential benefits of digital pathology to pathologists, clinicians and patients are compelling. In my new role as Aperio’s CMO, I see an opportunity to combine my passion for education and technology with my long-standing focus on improving patient care.”
Dr. Schwartz brings 30 years of pathology expertise to his new role as CMO, most recently serving as President of the College of American Pathologists, and Director of Pathology and Laboratory Medicine at Presbyterian Healthcare in Charlotte, North Carolina. Board certified in anatomic and clinical pathology with subspecialty boards in medical microbiology and cytopathology, he is a graduate of Duke University Medical School, where he completed his residency and fellowship training, and served as chief resident. He was appointed to the Clinical Laboratory Improvement Advisory Committee by HHS and is a current member. He was a co-chair and author of the ASCO/CAP Guidelines on HER2, which was published in the January 2007 editions of the Journal of Clinical Oncology and Archives of Pathology and Laboratory Medicine. He is currently a co-chair and one of the co-authors of the ASCO/CAP Guidelines on ER/PR, which will be published in both journals in 2010.
